OpportunityAnalyzer: Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018 is a new market research publication announced by Reportstack. Amyotrophic lateral sclerosis (ALS) is a rare, but fatal, motor neuron disease (MND) characterized by axonal degeneration and progressive loss of motor neurons. ALS affects both the upper (brain to spinal cord) and lower (brain stem to muscle tissue) motor neurons, gradually reducing a patient’s ability to initiate and control muscle movement. Muscle atrophy, starting in the periphery (arms and legs), ultimately leads to complete paralysis after several years of progressive worsening of muscle strength. Respiratory failure is the most common cause of death, as smooth muscle function becomes affected when the disease is in its final stages. The progressively degenerative course of the condition is a great burden for both patients and caregivers, as well as for society. ALS usually affects people age =40 years, and has a worldwide incidence of about two cases per 100,000 population, and a prevalence ranging between four and seven cases per 100,000.
Key Questions Answered
- How does the patent expiration of Rilutek effect the ALS market?
- The pipeline consists of novel but unproven mechanisms of action in ALS. Which of these therapies will attain high sales revenues during 2013-2018, and in which markets?
- How large an impact will Methycobal and Edaravone have on the ALS market in Japan? What do key opinion leaders think of these treatment approaches?
- What effects will advancing diagnostic and disease modeling capabilities have on drug development?
- What regulatory efforts are likely to affect drug development in the markets researched? Which is the largest growth market globally?
Key Findings
- Country-specific orphan drug and rare disease policy heavily influences development opportunities in the 7MM.
- Discovery of potential symptomatic and disease-modifying therapies in early stage clinical development is challenged by the absence of ALS biomarkers and disease staging that can demonstrate a patient’s response to treatment.
- Pharmaceutical products for ALS will face growing competition from gene and stem cell-based therapies.
- Advances in animal modeling are expected to have a significant impact on ALS drug development.
Scope
- Overview of ALS, including etiology and pathophysiology, general symptoms, quality of life, country-specific treatment recommendations and epidemiologic data.
- Annualized ALS market revenue, annual cost of treatment and usage patterns from 2013 and forecast for five years to 2018.
- Key topics covered include unmet needs analysis, research and development strategies, pipeline assessment, and pipeline valuation analysis for the ALS market.
- Pipeline valuation analysis: clinical and commercial benchmarking of AB Science’s AB-1010 (masitinib), Cytokinetics’ CK-2017357 (tirasemtiv), Mitsubishi Tanabe’s Radicut (edaravone), Eisai’s Methycobal (mecobalamin), and Orphazyme ApS’ arimoclomol.
- Assessment of the current and future market competition in the global ALS drug market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the ALS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ALS market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global ALS market from 2013-2018.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Key Questions Answered
- How does the patent expiration of Rilutek effect the ALS market?
- The pipeline consists of novel but unproven mechanisms of action in ALS. Which of these therapies will attain high sales revenues during 2013-2018, and in which markets?
- How large an impact will Methycobal and Edaravone have on the ALS market in Japan? What do key opinion leaders think of these treatment approaches?
- What effects will advancing diagnostic and disease modeling capabilities have on drug development?
- What regulatory efforts are likely to affect drug development in the markets researched? Which is the largest growth market globally?
Key Findings
- Country-specific orphan drug and rare disease policy heavily influences development opportunities in the 7MM.
- Discovery of potential symptomatic and disease-modifying therapies in early stage clinical development is challenged by the absence of ALS biomarkers and disease staging that can demonstrate a patient’s response to treatment.
- Pharmaceutical products for ALS will face growing competition from gene and stem cell-based therapies.
- Advances in animal modeling are expected to have a significant impact on ALS drug development.
Scope
- Overview of ALS, including etiology and pathophysiology, general symptoms, quality of life, country-specific treatment recommendations and epidemiologic data.
- Annualized ALS market revenue, annual cost of treatment and usage patterns from 2013 and forecast for five years to 2018.
- Key topics covered include unmet needs analysis, research and development strategies, pipeline assessment, and pipeline valuation analysis for the ALS market.
- Pipeline valuation analysis: clinical and commercial benchmarking of AB Science’s AB-1010 (masitinib), Cytokinetics’ CK-2017357 (tirasemtiv), Mitsubishi Tanabe’s Radicut (edaravone), Eisai’s Methycobal (mecobalamin), and Orphazyme ApS’ arimoclomol.
- Assessment of the current and future market competition in the global ALS drug market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the ALS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ALS market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global ALS market from 2013-2018.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
To view the table of contents and know more details please visit OpportunityAnalyzer: Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018.
The psychological support from the medical center was non-existent and if it were not for multivitamincare. org and the sensitive cure of their herbal formula he would have been not been alive today,there was significant improvement in the first 4 weeks of usage that gave us hope that my father will be alive,His doctor put him on riluzole, letting us know there was no cure until we gave try on multivitamincare. org supplement that cure him totally from this disease after 15 weeks of his usage.
ReplyDeleteThere is nothing positive about a cure ALS condition except for their herbal treatment .
xx